|RNA is the software of life . RNA tells your DNA what to do. Sequence your cancer’s DNA to discover what is needed to kill it .|
PERSONALIZE your drug treatment accordingly. This company has 20 drugs in development .Moderna has 21 mRNA investigational candidates in its pipeline with 13 candidates in clinical development stage
Oppenheimer ranks these shares a BUY with a $27 PRICE TARGET up 30% from current levels. 6 out of 7 analysts rate these shares a STRONG BUY .
We urge serious investors to place these shares on their BUY LIST
INSIDER INVESTS $1 MILLION BUYS 52,600 SHARES
Recently a director at Moderna Inc purchased more than 52,600 shares via trust. At $19.00 per share, that cost the director nearly $1.00 million. Note that the CEO and the president of the clinical-stage biotechnology company both were selling shares last week.
This vaccine-developer just received an important FDA approval for its Zika treatment. Shares have retreated more than 5% year to date and ended the week less than a dollar below the director’s purchase price. The consensus price target suggests there is more than 62% upside in Moderna stock.
Moderna does not have any marketed products in its portfolio. It derives revenues from its collaboration partners using its messenger RNA (mRNA) technology for development of therapies targeting different indications. These revenues depend on achievement of certain clinical development milestones by partnered pipeline candidates and can vary every quarter. In the first three quarters of 2019, revenues declined year over year due to lower collaboration revenues across all its strategic alliances, particularly with AstraZeneca AZN and Merck MRK.
We do not expect any improvement in the fourth quarter.Meanwhile, Moderna has 21 mRNA investigational candidates in its pipeline with 13 candidates in clinical development stage. With several ongoing pre-clinical and clinical studies, operating expenses increased year over year in the first nine months of 2019.
We expect operating expense to have increased in the soon-to-be-reported quarter as well.We note that the company has enough funds to continue its research activities. The company ended the September quarter with $1.34 billion in cash, cash equivalents and investments and expects to end the year with approximately $1.20 billion.Last month, Moderna announced a new partnership with Coalition for Epidemic Preparedness Innovations (“CEPI”) to develop a vaccine for the deadly coronavirus (2019-nCoV) outbreak in China.The company is also working with NIAID to develop the 2019-nCoV vaccine
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.